Feizy Abdolamir, Karami Aida, Eghdamzamiri Reza, Moghimi Minoosh, Taheri Hadi, Mousavinasab Nouraddin
Department of Pathology, Valiasr Hospital, Zanjan University of Medical Science, Zanjan, Iran. Email:
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1721-1725. doi: 10.22034/APJCP.2018.19.6.1721.
Background: The fourth most prevalent cancer worldwide and a major cause of death in developing countries is gastric cancer (GC). Human epidermal growth factor receptor 2 (HER2), is a proto-oncogene expressed in different solid tumors. This study aimed to evaluate possible associations of HER2 expression status with survival rate, age, sex, tumor grade, histopathological type, and primary tumor location in patients with GC. Methods: Subjects were enrolled in this cohort study after consideration of inclusion and exclusion criteria. Biopsy specimens were stained using immunohistochemistry. Samples with a score of 3+ were considered to exhibit HER2 overexpression. The mentioned variables were extracted from patients’ files as well as by clinical evaluation. The Kaplan-Meier method was applied for analyzing the survival rate and Chi square for possible factor associations. Results: A total of 210 patients (25.2% female and 74.8% male) were enrolled. In a 5-year follow-up (adherence rate: 45.7%), the average survival was 9.4±10.9 months. HER2 overexpression was evident in 24%. There was no statistically significant association found between HER2 expression and primary tumor location (p-value=0.63), histopathological type (p-value=0.72), or tumor grade (p-value=0.051). Furthermore, no statistically significant links were apparent with tumor grade in either male or female groups as well as patients aged ≥60 and ˂60 years (all p-values >0.05). Moreover, no statistically significant association was detected between HER2 expression status (p-value=0.88), sex (p-value=0.31), and age (p-value=0.055) with patient survival. Conclusions: No statistically meaningful association was found between all parameters examined and HER2 expression status. Divergence of the results from earlier studies might be due to genetic variation. Thus, performing a meta-analysis on certain races might be helpful for clarification.
胃癌(GC)是全球第四大常见癌症,也是发展中国家的主要死因。人表皮生长因子受体2(HER2)是一种在不同实体瘤中表达的原癌基因。本研究旨在评估HER2表达状态与GC患者生存率、年龄、性别、肿瘤分级、组织病理学类型和原发肿瘤部位之间的可能关联。方法:根据纳入和排除标准,将受试者纳入本队列研究。活检标本采用免疫组织化学染色。评分为3+的样本被认为存在HER2过表达。上述变量从患者病历以及临床评估中提取。采用Kaplan-Meier方法分析生存率,采用卡方检验分析可能的因素关联。结果:共纳入210例患者(女性占25.2%,男性占74.8%)。在5年随访中(依从率:45.7%),平均生存期为9.4±10.9个月。24%的患者存在HER2过表达。未发现HER2表达与原发肿瘤部位(p值=0.63)、组织病理学类型(p值=0.72)或肿瘤分级(p值=0.051)之间存在统计学显著关联。此外,在男性或女性组以及年龄≥60岁和<60岁的患者中,均未发现与肿瘤分级存在统计学显著关联(所有p值>0.05)。此外,未检测到HER2表达状态(p值=0.88)、性别(p值=0.31)和年龄(p值=0.055)与患者生存率之间存在统计学显著关联。结论:在所检查的所有参数与HER2表达状态之间未发现统计学上有意义的关联。结果与早期研究的差异可能是由于基因变异。因此,对某些种族进行荟萃分析可能有助于澄清。